3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
7
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Pain
2
Motor Activity
2
Hematopoietic and Lymphatic System Neoplasm
2
Carcinoma, Non-Small-Cell Lung
2
Breast Carcinoma In Situ
2
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Sedentary Behavior
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Pulmonary Disease, Chronic Obstructive
1
Polyps
1
Patient Satisfaction
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neuromuscular Junction Diseases
1
Nervous System Diseases
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Myasthenia Gravis
1
Muscle Weakness
1
Metastatic Pancreatic Adenocarcinoma
1
Malignant Hepatobiliary Neoplasm
1
Interventions
Surveys and Questionnaires
6
Standard of Care
6
Blood Specimen Collection
6
BNT162 Vaccine
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Specimen Handling
3
Practice Guidelines as Topic
3
COVID-19 Vaccines
3
2019-nCoV Vaccine mRNA-1273
3
tocilizumab
2
sotrovimab
2
Pandemic Preparedness
2
CVnCoV COVID-19 vaccine
2
Azithromycin
2
sinovac COVID-19 vaccine
1
selinexor
1
remdesivir
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
cilgavimab and tixagevimab drug combination
1
ciclesonide
1
avdoralimab
1
XAV-19
1
Therapeutics
1
Telemedicine
1
Sperm Count
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
COVID-19
×
Telemedicine
×
Clear all
NCT04357574
2026-02-06
CORONA-SHIELD
Duke University
Enrolling by invitation
1,000 enrolled